Popular Articles

Boston Arm Of Multi-City Study To Focus On Sexual Health, HIV Risk Among Black Gay, Bisexual Men
Boston-based Fenway Health and the Multicultural AIDS Coalition "have launched the recruitment phase of a new study aimed at learning more about the sexual health of black gay and bi[sexual] men and finding effective strategies for HIV prevention within the black gay community," Bay Windows reports. The study, called Project Saving Ourselves (SOS), is seeking to recruit up to 400 participants in Boston, and also is collecting data on black gay and bisexual men in New York, Washington, D.C., Atlanta, Los Angeles and San Francisco. Ben Perkins, Project SOS director at the Fenway Institute of Fenway Health"s research division, said, "This is pretty new. In terms of the scale, there hasn"t been anything quite like it." Perkins said there are several questions researchers hope to answer about black gay and bisexual male health and HIV prevention, but the goal is to determine what factors put them at risk for HIV and help promote better health and safe behavior (Jacobs, 7/15).
drugs without prescription
Obesity And Diabetes Reduced By Common Allergy Drug In Mouse Model
Crack open the latest medical textbook to the chapter on type 2, or adult-onset, diabetes, and you"ll be hard pressed to find the term "immunology" anywhere. This is because metabolic conditions and immunologic conditions are, with a few exceptions, distant cousins.
News of the day
What Is A Virus? What Is A Viral Infection?
A virus (from the Latin virus meaning toxin or poison) is a microscopic organism consisting of genetic material (RNA or DNA) surrounded by a protein, lipid (fat), or glycoprotein coat. Viruses are unique organisms because they cannot reproduce without a host cell. After contacting a host cell, a virus will insert genetic material into the host and take over the host"s functions. The cell, now infected, continues to reproduce, but it reproduces more viral protein and genetic material instead of its usual products. It is this process that earns viruses the classification of "parasite".
Oncology

2009/037 Update On NICE Appraisal Of Drugs For Alzheimer's Disease Following Court Of Appeal Ruling

The National Institute for Health and Clinical Excellence (NICE) has announced that, following consultation with stakeholders on the economic model that underpinned NICE"s 2006 guidance on the use of drugs to treat Alzheimer"s disease, the resulting draft guidance remains unchanged. In accordance with the Court of Appeal"s ruling on the economic model used in the technology appraisal of drugs for the treatment of Alzheimer"s disease, NICE released the fully executable version of the model to stakeholders for their comment in November 2008. Having fully reviewed all the resulting comments the Independent Advisory Committee concluded that, although a number of technical inaccuracies were highlighted and amendments were made to the economic model, these were not sufficient to change the original conclusion that these treatments are not cost effective in the mild stages of the disease. NICE guidance on the use of donepezil, galantamine and rivastigmine and memantine for the treatment of Alzheimer"s disease therefore remains unchanged and the drugs continue to be recommended only for people with moderate Alzheimer"s disease. Consultees now have a chance to appeal against this decision. Andrew Dillon, NICE Chief Executive said: "We have complied with the Court of Appeal"s ruling to release the executable version of the economic model used in this appraisal for consultation and to consider the comments made by consultees. Although these comments resulted in minor changes to the model, our Independent Advisory Committee concluded that these were not enough to make these treatments a cost-effective use of NHS res in the mild stages of the disease. He continued: "NICE was not asked by the Court of Appeal to carry out a new appraisal of these treatments. However, we operate a process of regularly reviewing our guidance to take into account any new evidence and as long as no appeals are received a review can start as soon as possible. "The decisions NICE makes are amongst the most difficult in public life and we will continue to work hard to ensure that our decision-making process is robust and transparent and works in the best interests of everyone who relies on the NHS for their care. Alzheimer"s disease is one of the most distressing and debilitating disorders but drug treatment is not the only option for these patients. This is why we have published a clinical guideline on the management of dementia (including Alzheimer"s disease) which outlines the package of medical and social care that should be available for people with dementia and their carers, including social, medical and psychological treatment from early detection through to end of life." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):